(Developmental Cell 44, 447–459.e1–e5; February 26, 2018) In the originally published version of the article, the Declaration of Interests section did not include a financial interest and patent application. At the time of publication, H.Z. owned 90 shares of Alnylam stock worth approximately $9,000. Figures S3E and S3F were performed in collaboration with Alnylam. In addition, H.Z. and S.Z. hold a patent application entitled “Inhibitory RNA-Based Therapeutics Targeting ANLN for Cancer Treatment (International Patent Application No. PCT/US2017/034142 based on U.S. Serial No. 62/347,803).” The Declaration of Interests section has been updated here and in the article online. This correction does not affect the results in the article or the conclusions of this study. The authors regret this oversight.
ASJC Scopus subject areas
- Molecular Biology
- Biochemistry, Genetics and Molecular Biology(all)
- Developmental Biology
- Cell Biology